[Changes in fibronectin concentration during therapeutic plasmapheresis. Therapeutic effectiveness of selective removal of fibronectin in immune complex pathology]. 1984

S A Vasil'ev, and V G Savchenko, and V M Gorodetskiĭ, and G A Ermolin, and V E Kotelianskiĭ

Variation in the concentration of plasma fibronectin (FN) seen during 65 sessions of therapeutic plasmapheresis was studied in 20 inpatients with the following diagnoses: acute leukemias (4), paraproteinemic hemoblastoses (5), Sjögren's syndrome (2), protracted septic endocarditis (1), systemic lupus erythematosus (17), acute polyradiculoneuritis (1), multiple sclerosis (3). The patients' age ranged within 19 to 64 years. There were 10 men and 10 women. The concentration of FN in 218 plasma samples was measured by the ELISA. It was discovered that plasma of healthy donors contained 200 to 400 micrograms/ml FN (M +/- 1.5 sigma). Prior to plasmapheresis the glycoprotein content in all the patients was on the average within normal (300 micrograms/ml). After the session the concentration of FN decreased almost two-fold (130 micrograms/ml); after 6 hours it was 175 micrograms/ml on the average, whereas after 24-48 hours it reached the initial level. Repeated plasmapheresis sessions carried out once every 3-4 days did not lead to the depletion of the FN pool, since its level reached the initial one over the first 24-48 hours. Such a mechanism was unchanged regardless of the initial level of FN recorded in the patients blood (high, normal or low). No relationship was found between FN deficiency which developed after plasmapheresis and infectious complications. It is assumed that FN deficiency per se cannot be responsible for the patients' decreased resistance to infection. Three patients received a series of selective plasmapheresis. Sjögren's syndrome and immune complex vasculitis was diagnosed in one female patient, hemorrhagic vasculitis due to chronic hepatitis in another female patient, the third female patient manifested gammapathy with cryoglobulinemia.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007105 Immune Complex Diseases Group of diseases mediated by the deposition of large soluble complexes of antigen and antibody with resultant damage to tissue. Besides SERUM SICKNESS and the ARTHUS REACTION, evidence supports a pathogenic role for immune complexes in many other IMMUNE SYSTEM DISEASES including GLOMERULONEPHRITIS, systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC) and POLYARTERITIS NODOSA. Hypersensitivity, Type III,Type III Hypersensitivity,Disease, Immune Complex,Diseases, Immune Complex,Hypersensitivities, Type III,Immune Complex Disease,Type III Hypersensitivities
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010956 Plasmapheresis Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use. Double Filtration Plasmapheresis,Therapeutic Immunoadsorption,Therapeutic Plasma Adsorption,Therapeutic Plasmapheresis,Adsorption, Therapeutic Plasma,Adsorptions, Therapeutic Plasma,Double Filtration Plasmaphereses,Filtration Plasmapheresis, Double,Immunoadsorption, Therapeutic,Plasma Adsorption, Therapeutic,Plasmaphereses,Plasmapheresis, Double Filtration,Plasmapheresis, Therapeutic,Therapeutic Immunoadsorptions,Therapeutic Plasma Adsorptions,Therapeutic Plasmaphereses
D005260 Female Females
D005353 Fibronectins Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins. Cold-Insoluble Globulins,LETS Proteins,Fibronectin,Opsonic Glycoprotein,Opsonic alpha(2)SB Glycoprotein,alpha 2-Surface Binding Glycoprotein,Cold Insoluble Globulins,Globulins, Cold-Insoluble,Glycoprotein, Opsonic,Proteins, LETS,alpha 2 Surface Binding Glycoprotein
D006438 Hemodilution Reduction of blood viscosity usually by the addition of cell free solutions. Used clinically (1) in states of impaired microcirculation, (2) for replacement of intraoperative blood loss without homologous blood transfusion, and (3) in cardiopulmonary bypass and hypothermia. Hemodilutions
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S A Vasil'ev, and V G Savchenko, and V M Gorodetskiĭ, and G A Ermolin, and V E Kotelianskiĭ
January 1994, Terapevticheskii arkhiv,
S A Vasil'ev, and V G Savchenko, and V M Gorodetskiĭ, and G A Ermolin, and V E Kotelianskiĭ
November 1984, Archives of pathology & laboratory medicine,
S A Vasil'ev, and V G Savchenko, and V M Gorodetskiĭ, and G A Ermolin, and V E Kotelianskiĭ
January 1986, The Tokai journal of experimental and clinical medicine,
S A Vasil'ev, and V G Savchenko, and V M Gorodetskiĭ, and G A Ermolin, and V E Kotelianskiĭ
January 1976, Journal of clinical pathology,
S A Vasil'ev, and V G Savchenko, and V M Gorodetskiĭ, and G A Ermolin, and V E Kotelianskiĭ
January 1987, European journal of haematology,
S A Vasil'ev, and V G Savchenko, and V M Gorodetskiĭ, and G A Ermolin, and V E Kotelianskiĭ
August 1987, European journal of haematology,
S A Vasil'ev, and V G Savchenko, and V M Gorodetskiĭ, and G A Ermolin, and V E Kotelianskiĭ
April 2022, Enfermedades infecciosas y microbiologia clinica (English ed.),
S A Vasil'ev, and V G Savchenko, and V M Gorodetskiĭ, and G A Ermolin, and V E Kotelianskiĭ
October 1997, The Annals of pharmacotherapy,
S A Vasil'ev, and V G Savchenko, and V M Gorodetskiĭ, and G A Ermolin, and V E Kotelianskiĭ
January 1989, Pediatriia,
S A Vasil'ev, and V G Savchenko, and V M Gorodetskiĭ, and G A Ermolin, and V E Kotelianskiĭ
January 2003, Journal of clinical apheresis,
Copied contents to your clipboard!